News Sentiment

CTOR sentiment intelligence

Citius Oncology, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 0.69 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.6% over one week, +4.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR)

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 1.6% Price digesting
Trend fit Trend inactive 4.1% over four weeks
Fair value -86.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 28
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
PR Newswire 12
TradingView 11
TradingKey 4
ChartMill 1
Investing.com 1
Investing.com Nigeria 1
Finviz 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 13
Analyst action 2
Balance sheet 2
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Stock Titan Direct company coverage

Citius Oncology (Nasdaq: CTOR) lines up $36.5M to fund LYMPHIR

Citius Oncology (Nasdaq: CTOR) has secured up to $36.5 million in financing to support the commercialization of its oncology therapy, LYMPHIR. This funding includes a senior secured term loan facility of up to $25 million from Avenue Capital Group and approximately $11.5 million

Tone
Positive 64/100
Event
Market update
Published
08 May 2026 02:09
Source
Stock Titan
Stock Titan Direct company coverage

Citius Oncology (NASDAQ: CTOR) registers 6.82M warrant shares, updates LYMPHIR trials and launch

Citius Oncology registered 6.82 million warrant shares and provided updates on its LYMPHIR product. The company shared positive Phase 1 trial data for LYMPHIR in combination with CAR-T therapy for DLBCL and with pembrolizumab for gynecologic cancers, demonstrating promising respo

Tone
Positive 64/100
Event
Market update
Published
07 May 2026 14:08
Source
Stock Titan
TradingView Direct company coverage

Citius Oncology Secures Up to $25M Term Loan and $11.5M Warrant Proceeds to Fund Commercialization

Citius Oncology has secured significant financing to bolster its liquidity for the commercialization of LYMPHIR and other corporate needs. The company obtained a secured term loan facility of up to $25 million from Avenue funds, with an initial draw of $10 million, and generated

Tone
Positive 76/100
Event
Balance sheet
Published
07 May 2026 11:40
Source
TradingView
Quantisnow Direct company coverage

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology announced the closing of an $18 million concurrent registered direct offering and private placement. The pricing for these offerings was at-the-market under Nasdaq rules. This financial move provides Citius Oncology with additional capital.

Tone
Positive 70/100
Event
Market update
Published
06 May 2026 11:09
Source
Quantisnow
PR Newswire Direct company coverage

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Citius Oncology, Inc. has secured up to $36.5 million in debt and equity capital to accelerate the commercialization of its FDA-approved drug, LYMPHIR®, for cutaneous T-cell lymphoma (CTCL). The financing includes a senior secured term loan facility of up to $25 million from Aven

Tone
Positive 82/100
Event
Balance sheet
Published
05 May 2026 23:39
Source
PR Newswire